Last verified: April 2026

FDA-Approved Synthetic Cannabinoids

Three cannabinoid-based pharmaceuticals have received FDA approval or international marketing authorization. They represent the legitimate pharmaceutical applications of cannabinoid receptor pharmacology:

Dronabinol (Marinol)

Dronabinol is synthetic Δ⁹-THC — chemically identical to the THC produced by the cannabis plant, but manufactured in a laboratory. It is formulated in sesame oil capsules and was the first cannabinoid pharmaceutical approved by the FDA:

• 1985: Approved for chemotherapy-induced nausea and vomiting (CINV) in patients who have failed conventional antiemetics
• 1992: Label expanded to include anorexia associated with weight loss in patients with AIDS

Dronabinol is classified as a Schedule III controlled substance — the same schedule as testosterone and anabolic steroids — while whole-plant cannabis containing the identical molecule remained Schedule I until the ongoing rescheduling process. This scheduling inconsistency has been one of the most frequently cited arguments against cannabis prohibition’s scientific rationale.

Dronabinol’s clinical utility is limited by the same pharmacological properties that define oral THC: slow and erratic absorption (peak effects 2–4 hours after dosing), extensive first-pass metabolism to 11-OH-THC (which contributes to variable and sometimes excessive psychoactive effects), and high interindividual variability in response. Many patients and clinicians report that whole-plant cannabis — particularly inhaled formulations — provides more predictable onset and easier titration than dronabinol capsules.

Nabilone (Cesamet)

Nabilone is a synthetic analog of THC — not chemically identical, but structurally similar with modified side chains that alter its pharmacokinetic profile. It was originally approved in 1985 but was withdrawn from the U.S. market due to limited demand, then reintroduced in 2006 for CINV refractory to conventional antiemetics.

Nabilone has slightly different receptor binding kinetics than dronabinol, with some evidence of greater potency and longer duration of action. It is also classified as Schedule II — more restrictive than dronabinol — reflecting the DEA’s assessment of its abuse potential at the time of scheduling.

Nabiximols (Sativex)

Nabiximols (brand name Sativex, GW Pharmaceuticals/Jazz Pharmaceuticals) is an oromucosal spray containing a botanical extract of Cannabis sativa standardized to 2.7 mg THC and 2.5 mg CBD per spray (approximately a 1:1 ratio). It is not purely synthetic — it is a whole-plant extract — but it is included here because it is a pharmaceutical cannabinoid product.

Nabiximols is approved in 29+ countries (primarily in Europe and Canada) for spasticity associated with multiple sclerosis. It has not been approved by the FDA for use in the United States, though clinical trials have been conducted in the U.S. The approximately 1:1 THC:CBD ratio represents a “Chemotype II” formulation that leverages CBD’s negative allosteric modulation of CB1 to temper THC’s psychoactive effects while preserving therapeutic activity.

Research Cannabinoids: The Tools of Discovery

Synthetic cannabinoids developed as research tools were essential to discovering the endocannabinoid system and remain critical for ongoing research. Two are particularly historically significant:

CP55,940 was synthesized at Pfizer in the 1970s as part of a cannabinoid structure-activity relationship program. It is a full agonist at both CB1 and CB2 with substantially higher potency than THC (approximately 45 times more potent at CB1). Critically, it was the radioligand used by Howlett and Devane in 1988 to demonstrate the existence of specific cannabinoid binding sites in rat brain — the experiment that proved cannabinoid receptors existed. Without CP55,940, the endocannabinoid system might have remained undiscovered for years longer.

WIN 55,212-2 is an aminoalkylindole compound structurally unrelated to THC that nonetheless activates CB1 and CB2 with high potency. It has been used extensively in research to characterize cannabinoid receptor signaling, particularly in electrophysiology studies of synaptic transmission. Its structural dissimilarity to THC demonstrated that cannabinoid receptor activation does not require a THC-like molecular scaffold — a finding that enabled the development of structurally diverse synthetic cannabinoids, including those later exploited for illicit purposes.

K2/Spice: Full Agonists and the Danger They Represent

The term “synthetic cannabinoids” in popular usage almost always refers to K2, Spice, and related illicit products: herbal material sprayed with synthetic full CB1 agonists and sold as legal alternatives to cannabis. These products represent a fundamentally different pharmacological category from plant cannabis, and the distinction is literally a matter of life and death.

The critical pharmacological difference:

• THC is a partial CB1 agonist — it can only activate the receptor to a fraction of its maximum capacity, producing a ceiling effect that limits toxicity regardless of dose
• K2/Spice compounds are full CB1 agonists — they can activate CB1 to its maximum capacity, with no ceiling effect. Dose-response curves continue to escalate without the built-in safety brake that partial agonism provides

This is not an incremental difference. It is a qualitative pharmacological distinction that explains why K2/Spice can cause seizures, psychosis, rhabdomyolysis, acute kidney injury, coagulopathy, and death — outcomes that are essentially impossible from THC alone.

Common K2/Spice compounds include:

• JWH-018 (named after John W. Huffman, the Clemson University chemist whose published research on synthetic cannabinoids was exploited by illicit manufacturers)
• AB-FUBINACA, AB-CHMINACA, ADB-BUTINACA — successive generations of increasingly potent full agonists developed as law enforcement scheduled previous compounds
• 5F-MDMB-PICA, MDMB-4en-PINACA — ultra-potent compounds associated with mass casualty events

The potency escalation is alarming. Some recent K2/Spice compounds have CB1 affinities in the sub-nanomolar range — hundreds to thousands of times more potent than THC. This means that minute dosing errors during the spraying process can produce products with catastrophically variable potency. “Hot spots” — regions of the herbal substrate with concentrated synthetic cannabinoid — have been directly linked to overdose clusters.

Why “Synthetic Marijuana” Is a Dangerous Misnomer

Media and law enforcement routinely refer to K2/Spice as “synthetic marijuana” or “fake weed.” This terminology is dangerously misleading because it implies that these products are equivalent to or substitutable for plant cannabis. They are not. The pharmacological distinction between a partial agonist (THC) and a full agonist (K2/Spice compounds) is as significant as the distinction between aspirin and fentanyl — both are analgesics, but they have entirely different risk profiles.

A person who uses cannabis without serious incident and then tries K2/Spice expecting a similar experience may be exposed to a compound that is orders of magnitude more potent, has no ceiling effect, and can produce life-threatening toxicity. The misnomer “synthetic marijuana” directly enables this dangerous misapprehension.

The Irony of Prohibition

The K2/Spice market exists primarily as a consequence of cannabis prohibition. The products were developed to circumvent drug testing and drug laws by using compounds that were technically legal (not explicitly scheduled) and undetectable on standard urine immunoassays. In jurisdictions with legal cannabis access, demand for synthetic alternatives is substantially lower.

John W. Huffman himself has publicly stated that he never intended his research compounds to be consumed by humans and has expressed dismay at their exploitation. His published structure-activity relationship data — intended to advance understanding of the endocannabinoid system — was used by clandestine chemists as a recipe book for manufacturing K2/Spice compounds. This represents one of the starkest examples of dual-use research concerns in pharmacology.

The difference between THC and synthetic cannabinoids is not one of degree — it is one of kind. A partial agonist and a full agonist at the same receptor produce fundamentally different toxicity profiles.

Paul Prather, Department of Pharmacology, University of Arkansas for Medical Sciences